These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19396651)

  • 1. Patient preference compared with random allocation in short-term psychodynamic supportive psychotherapy with indicated addition of pharmacotherapy for depression.
    Van HL; Dekker J; Koelen J; Kool S; van Aalst G; Hendriksen M; Peen J; Schoevers R
    Psychother Res; 2009 Mar; 19(2):205-12. PubMed ID: 19396651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
    Whyte EM; Basinski J; Farhi P; Dew MA; Begley A; Mulsant BH; Reynolds CF
    J Clin Psychiatry; 2004 Dec; 65(12):1634-41. PubMed ID: 15641868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.
    Vitiello B; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller MB; Birmaher B; Ryan ND; Kennard B; Mayes TL; DeBar L; Lynch F; Dickerson J; Strober M; Suddath R; McCracken JT; Spirito A; Onorato M; Zelazny J; Porta G; Iyengar S; Brent DA
    J Clin Psychiatry; 2011 Mar; 72(3):388-96. PubMed ID: 21208583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does early response predict outcome in psychotherapy and combined therapy for major depression?
    Van HL; Schoevers RA; Kool S; Hendriksen M; Peen J; Dekker J
    J Affect Disord; 2008 Jan; 105(1-3):261-5. PubMed ID: 17521743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression.
    McMakin DL; Olino TM; Porta G; Dietz LJ; Emslie G; Clarke G; Wagner KD; Asarnow JR; Ryan ND; Birmaher B; Shamseddeen W; Mayes T; Kennard B; Spirito A; Keller M; Lynch FL; Dickerson JF; Brent DA
    J Am Acad Child Adolesc Psychiatry; 2012 Apr; 51(4):404-11. PubMed ID: 22449646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine.
    Lin CH; Lin KS; Lin CY; Chen MC; Lane HY
    J Clin Psychiatry; 2008 Jan; 69(1):54-9. PubMed ID: 18312038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined brief dynamic therapy and pharmacotherapy in the treatment of major depressive disorder: a pilot study.
    Maina G; Rosso G; Crespi C; Bogetto F
    Psychother Psychosom; 2007; 76(5):298-305. PubMed ID: 17700050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial.
    Kocsis JH; Gelenberg AJ; Rothbaum BO; Klein DN; Trivedi MH; Manber R; Keller MB; Leon AC; Wisniewski SR; Arnow BA; Markowitz JC; Thase ME;
    Arch Gen Psychiatry; 2009 Nov; 66(11):1178-88. PubMed ID: 19884606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients.
    Alexopoulos GS; Katz IR; Reynolds CF; Carpenter D; Docherty JP;
    Postgrad Med; 2001 Oct; Spec No Pharmacotherapy():1-86. PubMed ID: 17205639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying patients at risk of complete nonresponse in the outpatient treatment of depression.
    Van HL; Dekker J; Peen J; van Aalst G; Schoevers RA
    Psychother Psychosom; 2008; 77(6):358-64. PubMed ID: 18701832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing treatment outcomes for patients with depression and generalized anxiety disorder.
    Thase ME; Trivedi M
    Psychopharmacol Bull; 2002; 36 Suppl 2():93-102. PubMed ID: 12490825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine.
    Alpert JE; Papakostas G; Mischoulon D; Worthington JJ; Petersen T; Mahal Y; Burns A; Bottiglieri T; Nierenberg AA; Fava M
    J Clin Psychopharmacol; 2004 Dec; 24(6):661-4. PubMed ID: 15538131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
    Bauer M; Tharmanathan P; Volz HP; Moeller HJ; Freemantle N
    Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):172-85. PubMed ID: 19165525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
    Vis PM; van Baardewijk M; Einarson TR
    Ann Pharmacother; 2005 Nov; 39(11):1798-807. PubMed ID: 16189284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient outcomes with education, drug therapy, and support: a study of venlafaxine ER-treated outpatients with major depressive disorder.
    Lobello K; Reddy S; Musgnung J; Pedersen R; Ninan PT
    Psychopharmacol Bull; 2010; 43(2):28-44. PubMed ID: 21052041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Questions raised by the failure of a trial of short-term psychodynamic therapy versus pharmacotherapy for major depressive disorder.
    Kocsis JH
    J Clin Psychiatry; 2012 Jan; 73(1):64-5. PubMed ID: 22316577
    [No Abstract]   [Full Text] [Related]  

  • 18. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.
    Thase ME; Friedman ES; Biggs MM; Wisniewski SR; Trivedi MH; Luther JF; Fava M; Nierenberg AA; McGrath PJ; Warden D; Niederehe G; Hollon SD; Rush AJ
    Am J Psychiatry; 2007 May; 164(5):739-52. PubMed ID: 17475733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.
    Woldu H; Porta G; Goldstein T; Sakolsky D; Perel J; Emslie G; Mayes T; Clarke G; Ryan ND; Birmaher B; Wagner KD; Asarnow JR; Keller MB; Brent D
    J Am Acad Child Adolesc Psychiatry; 2011 May; 50(5):490-8. PubMed ID: 21515198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.